Drug profile · INN
ticagrelor
ARX-TICAGRELOR
ticagrelor (ARX-TICAGRELOR) is a purinergic receptor p2y12 negative allosteric modulator. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Drug details — ticagrelor
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- ORAL
- Patents
- 1
- Programs
- 24
- Data quality
- 0.89
Quick answer
ticagrelor (ARX-TICAGRELOR) is a purinergic receptor p2y12 negative allosteric modulator. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Purinergic receptor P2Y12 negative allosteric modulator
Primary target: P2Y purinoceptor 12
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ticagrelor?
ticagrelor (ARX-TICAGRELOR) is a purinergic receptor p2y12 negative allosteric modulator. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ticagrelor?
ARX-TICAGRELOR is a marketed brand name for ticagrelor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ticagrelor?
ticagrelor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.